Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487426 | 1.00 | MEN1 (0.50) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL8062276 | 0.82 | GAA (0.40) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL24167605 | 0.79 | KMT2A (0.52) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL15287339 | 0.78 | MAPT (0.46) | MEN1KMT2ANPC1RAB9APOLB | |
| SCHEMBL962604 | 0.76 | ALDH1A1 (0.48) | MEN1KMT2AGAARAB9APOLB | |
| SCHEMBL13696709 | 0.76 | GAA (0.52) | MEN1KMT2AGAANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL31554813 | 0.75 | NPSR1 (0.53) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL14264702 | 0.74 | GAA (0.41) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL960636 | 0.74 | MAPT (0.61) | MEN1KMT2AGAANPC1RAB9A | |
| SCHEMBL960634 | 0.74 | MAPT (0.61) | MEN1KMT2AGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256461-B1 | UREA AND SULFONAMIDE DERIVATIVES AS HUMAN HELICASE DDX3 INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2023-09-13 | — | — | EP | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-10961261-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961261-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3609504-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | Anacor Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018160845-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-8268835-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7622605-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | PFIZER INC | 2009-11-12 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | RNASE1, GTF3C4, POLRMT | MEN1 4874/4885KMT2A 3005/4885GAA 320/4885 |
| US-11691992-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | MEN1 3036/4885KMT2A 4439/4885GAA 252/4885 |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | MEN1 4874/4885KMT2A 3005/4885GAA 320/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | MEN1 4874/4885KMT2A 3005/4885GAA 320/4885 |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | OXA1L, AOX1, EPX | MEN1 3567/4885KMT2A 4486/4885GAA 370/4885 |
| US-10961261-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | MEN1 3036/4885KMT2A 4439/4885GAA 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.